Monograph Details
|
|
Neoplasms
> Hormones and antagonists
|
|
LYSODREN |
| Manufacturer |
|
Bristol-Myers Squibb |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Adrenal cytotoxic agent. |
| Generic Name |
|
Mitotane 500mg; tabs; scored. |
| Indications |
|
Inoperable adrenal cortical carcinoma. |
| Children |
|
Not recommended. |
| Adults |
|
2–6g/day in divided doses (3–4 times/day). Doses may be increased incrementally to 9–10g/day. Max: 18–19g/day. Continue as long as clinical benefit observed. |
| Precautions |
|
Discontinue temporarily following shock or severe trauma. Hepatic disease. Remove any tumor tissues from metastatic masses prior to therapy to minimize possible infarction and hemorrhage. Long-term administration of high doses: assess behavioral and neurological function. May need concomitant steroid replacement. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Monitor oral anticoagulants. Caution with other drugs susceptible to hepatic enzyme induction. |
| Adverse Reactions |
|
GI upset, lethargy, somnolence, dizziness, vertigo, rash. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
